The latest articles from BioStock
» BioInvent presents positive interim data
» Positive Phase II results for Curasight in head and neck cancer
» DexTech takes the next step with OsteoDex
» Lumito's rights issue will enable launch in 2022
» BioStock Studio: Idogen has optimized IDO 8 for clinical phase
Pharmacologist and expands existing agreement to include sales of WasteLog and related services to Mexico. Read morePharmacolog also announces that Codonics is ordering an additional eight WasteLog-system. Read more.
Iconovo establishes the subsidiary Iconovo Pharma for pharmaceutical sales in the Nordic region. Read more.
2cureX launches IndiTreat mCRC Start test to guide first-line treatment for patients with metastatic colorectal cancer. Read more.
Board members, management team and the largest shareholders in Lumito subscribes units. Read more.
AroCell announces today that a new study has been started in South Sudan to evaluate the company's product TUBEX TF. Read more.
Implantica conducts successful cadaveric implantations of a number of pipeline products with multiple related tests in the cadaveric lab. Read more.
Biohit provides an update regarding GastroPanel. Read more.
Janssen presents new study results for vaccine candidate against RSV in adults. Read moreThe company also announces new data regarding Ciltacabtagene Autoleucel, read more, and that Rybrevant has been granted conditional marketing authorisation, read more.
Board member buys shares in Curasight. Read moreThe company will conduct a presentation regarding prostate cancer at HC Andersen Capital on December 15. Read more.
Subscription period in Targovax The issue ends today. Read more.
Today, December 14th, is the last trading day in Cessatechs series TO1. Read more.
Q-line strengthens the management team. Read more.
Modus Therapeutics participates in Stocks Live Sessions. Read more.
Vistin Pharma publishes financial calendar. Read more.
BergenBio will present at DNB Nordic Healthcare Conference 2021. Read moreThe company also presented at ASH. Read more.
Notices of general meetings:
Communiqués:
Reports:
News received since yesterday lunch:
WntResearch has filed a patent application for the treatment of Acute Myeloid Leukemia. Read more.
Chordate Medical have chosen American RQM+ to prepare an application for marketing authorization in the USA. Read more.
Cantargia reported positive results for the antibody CAN10 in a preclinical model of systemic sclerosis. Read more.
The sale of Karolinska Developments portfolio company Forendo Pharma to Organon has been successfully completed. Read more.
Aprea Therapeutics presented updated data during ASH-conference from the phase II study with eprenetapopt and Azacitidine in TP53-mutated MDS and AML. Read more.
Sobi and Apellis Pharmaceuticals presented results that showed that Aspaveli/Empaveli provides normalization and stabilization of clinical values in a broad PNH patient population. Read more.
Episurf Medicals implants have been approved for sale in Saudi Arabia. Read more.
NextCell Pharma has entered into a cooperation agreement with TAD1, a non-profit organization whose purpose is to increase knowledge in society about type 1 diabetes. Read more.
Realhearts surgeon gave a TED Talk about artificial hearts. Read more.
Ray Intelligence has signed an agreement with To aimRead more.
Christian Gyllenberg takes on the role of new Chief Financial Officer at GPX Medical on January 1, 2022 in line with the company's succession planning. Read more.
Intellego has received orders from HAI Solutions, conditional FDA-approval. Read more.
Xbrane Biopharma announced that it is initiating development of two new biosimilar candidates to the reference products Keytruda respectively Darzalex. Read more.
PCI Biotech provided an update regarding the RELEASE study. Read more.
Allarity Therapeutics informed of delisting from Nasdaq First North. Read more.
Aktiespararna has published an interview with Attanas et al. Read more.
ContextVision published financial calendar. Read more.
Novo Nordisk announced its share buyback program. Read more.
This morning's winner: Xbrane Biopharma 15,6%, Spago Nanomedical 7,3%, Pharmacolog 6,4%, Alteco 6,1%, Paxman 5%
This morning's losers: iZafe group -8%, Scandidos -7,2%, Allarity Therapeutics -6,7%, Enorama Pharma -6,5%, Bonzun -6,5%
Index: OMXS30 2311 +0,06%, Healthcare -0,87%
More articles from BioStock